亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Mortality rates in Alzheimer's disease and non-Alzheimer's dementias: a systematic review and meta-analysis

痴呆 荟萃分析 医学 危险系数 科克伦图书馆 队列研究 阿尔茨海默病 疾病 系统回顾 老年学 梅德林 置信区间 内科学 政治学 法学
作者
Chih‐Sung Liang,Dian‐Jeng Li,Fu‐Chi Yang,Ping‐Tao Tseng,André F. Carvalho,Brendon Stubbs,Trevor Thompson,Christoph Mueller,Jae Il Shin,Joaquim Raduà,Robert Stewart,Tarek K. Rajji,Yu‐Kang Tu,Tien‐Yu Chen,Ta‐Chuan Yeh,Chia‐Kuang Tsai,Chia‐Ling Yu,Chih‐Chuan Pan,Che‐Sheng Chu
出处
期刊:The Lancet Healthy Longevity [Elsevier]
卷期号:2 (8): e479-e488 被引量:161
标识
DOI:10.1016/s2666-7568(21)00140-9
摘要

People with dementia die prematurely. Identifying differences in mortality rates between different types of dementia might aid in the development of preventive interventions for the most vulnerable populations. The aim of this study was to compare the difference in mortality rates between individuals without dementia and individuals with various types of dementia.For this systematic review and meta-analysis, we did a systematic search of MEDLINE, PubMed, Embase, and Cochrane Library from inception to July 11, 2020, for cross-sectional or cohort studies that assessed mortality and survival-related outcomes among people with different types of dementia compared with people without dementia. Single-arm studies without comparison groups and autopsy studies or family studies that used a selected sample were excluded. The Newcastle-Ottawa Scale was used by two authors (D-JL and C-SC) independently to measure the methodological quality of included studies, and two authors (F-CY and P-TT) independently extracted data. We assessed differences in all-cause mortality rate and survival time from dementia diagnosis between individuals without dementia, individuals with Alzheimer's disease, and individuals with non-Alzheimer's disease dementias. The secondary outcomes were age at death and survival time from disease onset. Random-effects meta-analyses were done. Effect sizes included hazard ratios (HRs) and mean differences (MDs) with 95% CIs. Potential moderators, including age-associated moderators, were identified through meta-regression and subgroup analyses. This study is registered with PROSPERO, CRD42020198786.Our database search identified 11 973 records, and we included 78 eligible studies in our analyses, encompassing 63 125 individuals with dementia and 152 353 controls. Individuals with any type of dementia had a higher mortality rate than individuals without dementia (HR 5·90, 95% CI 3·53 to 9·86), and the HR for all-cause mortality was highest for Lewy body dementia (17·88, 5·87 to 54·46). After diagnosis, the mean survival time for people with Alzheimer's disease was 5·8 years (SD 2·0). Compared with people with Alzheimer's disease, a diagnosis of any non-Alzheimer's disease dementia was associated with a higher risk of all-cause mortality (HR 1·33, 1·21 to 1·46), a shorter survival time from diagnosis (MD -1·12 years, 95% CI -1·52 to -0·72), and a younger age at death (-1·76 years, -2·66 to -0·85). Survival time from disease onset was also shorter in people with non-Alzheimer's dementia, across types, compared with people with Alzheimer's disease, but the subgroup analysis revealed that this difference was only significant for vascular dementia (MD -1·27 years, -1·90 to -0·65) and dementia with Lewy bodies (MD -1·06 years, -1·68 to -0·44). The interactions between age and several survival-related outcomes were significant. 39 (50%) of the 78 included studies were rated as good quality, and large heterogeneity (I2>75%) was observed for most of the study outcomes.Alzheimer's disease is the most common type of dementia and one of the major causes of mortality worldwide. However, the findings from the current study suggest that non-Alzheimer's disease dementias were associated with higher morality rates and shorter life expectancy than Alzheimer's disease. Developing tailored treatment and rehabilitation programmes for different types of dementia is important for mental health providers, patients, and their families.None.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
搜集达人应助科研通管家采纳,获得10
刚刚
和风完成签到 ,获得积分10
2秒前
俏以完成签到,获得积分10
37秒前
体贴静竹完成签到 ,获得积分10
54秒前
1分钟前
星辰大海应助科研通管家采纳,获得10
2分钟前
清晨仪仪发布了新的文献求助10
2分钟前
2分钟前
朴素尔阳发布了新的文献求助10
2分钟前
2分钟前
webmaster完成签到,获得积分10
2分钟前
向东是大海完成签到,获得积分10
2分钟前
2分钟前
CC发布了新的文献求助10
3分钟前
万能图书馆应助清晨仪仪采纳,获得30
3分钟前
Yihan完成签到,获得积分10
3分钟前
科研王者发布了新的文献求助10
3分钟前
老万的小迷弟完成签到,获得积分10
3分钟前
JoeyJin完成签到,获得积分10
3分钟前
我是老大应助科研王者采纳,获得10
3分钟前
4分钟前
yeeeee发布了新的文献求助10
4分钟前
ttkx发布了新的文献求助10
4分钟前
CipherSage应助yeeeee采纳,获得10
5分钟前
量子星尘发布了新的文献求助10
5分钟前
5分钟前
5分钟前
artos发布了新的文献求助30
5分钟前
Lucas应助科研通管家采纳,获得10
6分钟前
科研通AI6应助artos采纳,获得10
6分钟前
华仔应助CC采纳,获得30
6分钟前
7分钟前
CC发布了新的文献求助30
7分钟前
执着梦柏完成签到 ,获得积分10
7分钟前
7分钟前
7分钟前
SciGPT应助科研通管家采纳,获得10
8分钟前
8分钟前
清晨仪仪发布了新的文献求助30
8分钟前
8分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Basic And Clinical Science Course 2025-2026 3000
《药学类医疗服务价格项目立项指南(征求意见稿)》 880
花の香りの秘密―遺伝子情報から機能性まで 800
3rd Edition Group Dynamics in Exercise and Sport Psychology New Perspectives Edited By Mark R. Beauchamp, Mark Eys Copyright 2025 600
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
nephSAP® Nephrology Self-Assessment Program - Hypertension The American Society of Nephrology 550
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5622241
求助须知:如何正确求助?哪些是违规求助? 4707275
关于积分的说明 14938986
捐赠科研通 4769648
什么是DOI,文献DOI怎么找? 2552255
邀请新用户注册赠送积分活动 1514348
关于科研通互助平台的介绍 1475053